Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
- Conditions
- Recurrent Ovarian CancerSignal Transduction Pathway DeregulationTherapy-Associated Cancer
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
- Target Recruit Count
- 148
- Registration Number
- NCT03458221
- Locations
- 🇳🇱
Elisabeth-Tweesteden Hospital, Tilburg, Netherlands
🇳🇱Catharina Ziekenhuis, Eindhoven, Brabant, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 30
- Registration Number
- NCT03358563
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
- Conditions
- Stage I Prostate AdenocarcinomaStage II Prostate Adenocarcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT03147196
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Conditions
- Prostate Cancer
- Interventions
- Radiation: Salvage radiation
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 345
- Registration Number
- NCT03141671
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Ribociclib and Bicalutamide in AR+ TNBC
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Kari Wisinski
- Target Recruit Count
- 37
- Registration Number
- NCT03090165
- Locations
- 🇺🇸
Michigan State University, Lansing, Michigan, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Stage II Prostate Adenocarcinoma AJCC v7Stage I Prostate Adenocarcinoma AJCC v7Stage III Prostate Adenocarcinoma AJCC v7
- Interventions
- Radiation: External Beam Radiation TherapyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇵🇷
Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico
🇺🇸AdventHealth Celebration, Celebration, Florida, United States
🇺🇸GenesisCare USA - Aventura, Aventura, Florida, United States
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- Drug: TPC
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT03055312
- Locations
- 🇨🇳
Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2023-02-16
- Target Recruit Count
- 26
- Registration Number
- NCT03043807
- Locations
- 🇺🇸
Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Xu fei
- Target Recruit Count
- 58
- Registration Number
- NCT02910050
- Locations
- 🇨🇳
State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Definitive Treatment
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT02742675
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.